Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A2TSL71
Thu, 10.11.2022
SYNLAB AG
SYNLAB reports strong underlying performance in 9M 2022, confirms 2022 guidance and releases 2023 guidance
Robust 9M 2022 performance with revenue of €2.5 billion
Strong underlying organic growth (excluding COVID-19 related revenues): +6.3% in 9M 2022 and +4.1% in Q3 2022, well above our mid-term organic growth target
COVID-19 testing revenue €72 [ … ]
Thu, 27.10.2022
SYNLAB AG
SYNLAB and Microba reinforce their combined expertise and expand strategic agreement on advanced gut microbiome test myBIOME
Launched in Spain and Colombia in 2020, myBIOME is an innovative gut microbiome examination based on technology developed by Microba’s leading researchers in the field of microbiome analysis.
The combination of leading-edge [ … ]
Thu, 27.10.2022
SYNLAB AG
SYNLAB and Microba reinforce their combined expertise and expand strategic agreement on advanced gut microbiome test myBIOME
Launched in Spain and Colombia in 2020, myBIOME is an innovative gut microbiome examination based on technology developed by Microba’s leading researchers in the field of microbiome analysis.
The combination of leading-edge [ … ]
Thu, 11.08.2022
SYNLAB AG
Robust H1 2022 performance with revenue of €1.85 billion
Strong underlying organic growth (excluding COVID-19 related revenues): +7.2% in H1 2022 and +4.0% in Q2 2022
Higher than expected COVID-19 testing revenue: €618 million in H1 2022 (€164 million in Q2 2022)
Ten bolt-on and specialty acquisitions completed in H1 2022 in seven countries ( [ … ]
Thu, 11.08.2022
SYNLAB AG
Robust H1 2022 performance with revenue of €1.85 billion
Strong underlying organic growth (excluding COVID-19 related revenues): +7.2% in H1 2022 and +4.0% in Q2 2022
Higher than expected COVID-19 testing revenue: €618 million in H1 2022 (€164 million in Q2 2022)
Ten bolt-on and specialty acquisitions completed in H1 2022 in seven countries ( [ … ]
Thu, 12.05.2022
SYNLAB AG
Revenue of €1.06 billion, +13.1% growth vs. Q1 2021
Non-COVID-19[1] testing organic revenue growth of +10.8% vs. Q1 2021
COVID-19 testing revenue slightly higher than in Q1 2021: volume surge more than offset PCR price drop
Adjusted EBITDA of €357 million, very high margin at 33.6%
Unlevered free cash flow of €155 million
Eight acquisitions co [ … ]
Tue, 10.05.2022
SYNLAB AG
SYNLAB Medical Congress: making healthcare future-proof with advanced diagnostics
Hosting its 2022 Medical Congress, SYNLAB builds upon its unique diagnostic expertise and brings together medical experts from across the globe to develop medical solutions addressing patients’ needs of today and tomorrow
ANTIMICROBIAL RESISTANCE: Fighting this leadi [ … ]
Mon, 09.05.2022
SYNLAB AG
On 24 March 2022, SYNLAB AG (the "Company") announced, with the approval of the supervisory board of the Company, the resolution of the management board of the Company (both dated 24 March 2022), to repurchase up to 660,566 shares in the Company (the "Share Buy-Back Program 2022"). The annual general meeting of the Company of 27 April 2021 had auth [ … ]
Fri, 29.04.2022
SYNLAB AG
SYNLAB International GmbH
Moosacher Straße 88
80809 Munich
Germany
ESG Report 2021: SYNLAB defines high-impact areas to drive its ambitious environmental, social and governance agenda
Building on SYNLAB's clearly defined ESG focus areas SYNLAB Green, SYNLAB Care, and SYNLAB Citizenship, as well as its commitment to the United Nations Sustainabl [ … ]
Tue, 29.03.2022
SYNLAB AG
SYNLAB partners with OncoDNA to provide comprehensive biomarker testing for cancer therapy selection in Germany
SYNLAB will provide high-quality, pan-cancer OncoDEEP(R) biomarker test to optimize prediction of patient responses to a wide range of approved and experimental therapies
The comprehensive test will help oncologists decide on the most ef [ … ]